Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) posted its earnings results on Wednesday. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03), Zacks reports. The business had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $2.64 on Friday. Aclaris Therapeutics has a one year low of $0.59 and a one year high of $5.61. The company has a market cap of $188.36 million, a price-to-earnings ratio of -3.22 and a beta of 0.10. The business’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.26.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.